Class information for:
Level 1: TELAVANCIN//CEFTAROLINE//LIPOGLYCOPEPTIDE

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
11854 949 34.1 75%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
7 4 INFECTIOUS DISEASES//MICROBIOLOGY//VIROLOGY 1353914
73 3       MICROBIOLOGY//INFECTIOUS DISEASES//STAPHYLOCOCCUS AUREUS 82747
575 2             VANCOMYCIN//LINEZOLID//DAPTOMYCIN 14274
11854 1                   TELAVANCIN//CEFTAROLINE//LIPOGLYCOPEPTIDE 949

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 TELAVANCIN authKW 1946361 7% 86% 70
2 CEFTAROLINE authKW 1688571 7% 80% 66
3 LIPOGLYCOPEPTIDE authKW 1649635 6% 93% 55
4 DALBAVANCIN authKW 1375446 6% 75% 57
5 CEFTOBIPROLE authKW 1081641 5% 78% 43
6 ORITAVANCIN authKW 843732 4% 67% 39
7 CEFTAROLINE FOSAMIL authKW 622900 2% 88% 22
8 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS authKW 371930 2% 68% 17
9 ABSSSI authKW 274175 1% 61% 14
10 AWARE authKW 165469 1% 86% 6

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Microbiology 21497 62% 0% 590
2 Infectious Diseases 14606 37% 0% 351
3 Pharmacology & Pharmacy 11617 64% 0% 604
4 Immunology 170 8% 0% 78
5 Chemistry, Medicinal 41 3% 0% 26
6 Toxicology 12 2% 0% 18
7 Critical Care Medicine 12 1% 0% 10
8 Health Care Sciences & Services 11 1% 0% 11
9 Medicine, General & Internal 4 3% 0% 27
10 Biotechnology & Applied Microbiology 2 2% 0% 21

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 ANTIINFECT CHEM 100543 1% 63% 5
2 MS MICROBIOL 673 64350 0% 100% 2
3 ANTIINFECT DEV 54118 2% 8% 21
4 ANTIINFECT 44963 2% 7% 20
5 UNITE PHARMACOL CELLULAIRE MOL 39243 1% 10% 12
6 BEAVER KREEK 345 34261 1% 15% 7
7 ABDOMINAL TRAUMATOL ORTHOPED SURG 32175 0% 100% 1
8 ADJUNCT INFECT DIS 32175 0% 100% 1
9 ADULT ANTIMICROBIAL STEWARDSHIP PHARM 32175 0% 100% 1
10 AFFILIATED HOSP P DIS 1 32175 0% 100% 1

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 82769 26% 1% 246
2 DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE 27124 7% 1% 67
3 JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 23733 10% 1% 96
4 INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS 19347 5% 1% 48
5 EXPERT REVIEW OF ANTI-INFECTIVE THERAPY 5506 1% 1% 13
6 CLINICAL INFECTIOUS DISEASES 4804 5% 0% 44
7 FUTURE MICROBIOLOGY 3887 1% 1% 11
8 INFECTIONS IN SURGERY 3216 0% 10% 1
9 THERAPEUTICS AND CLINICAL RISK MANAGEMENT 2662 1% 1% 8
10 INFECTION AND DRUG RESISTANCE 2469 0% 3% 3

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 TELAVANCIN 1946361 7% 86% 70 Search TELAVANCIN Search TELAVANCIN
2 CEFTAROLINE 1688571 7% 80% 66 Search CEFTAROLINE Search CEFTAROLINE
3 LIPOGLYCOPEPTIDE 1649635 6% 93% 55 Search LIPOGLYCOPEPTIDE Search LIPOGLYCOPEPTIDE
4 DALBAVANCIN 1375446 6% 75% 57 Search DALBAVANCIN Search DALBAVANCIN
5 CEFTOBIPROLE 1081641 5% 78% 43 Search CEFTOBIPROLE Search CEFTOBIPROLE
6 ORITAVANCIN 843732 4% 67% 39 Search ORITAVANCIN Search ORITAVANCIN
7 CEFTAROLINE FOSAMIL 622900 2% 88% 22 Search CEFTAROLINE+FOSAMIL Search CEFTAROLINE+FOSAMIL
8 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS 371930 2% 68% 17 Search ACUTE+BACTERIAL+SKIN+AND+SKIN+STRUCTURE+INFECTIONS Search ACUTE+BACTERIAL+SKIN+AND+SKIN+STRUCTURE+INFECTIONS
9 ABSSSI 274175 1% 61% 14 Search ABSSSI Search ABSSSI
10 AWARE 165469 1% 86% 6 Search AWARE Search AWARE

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 VAN BAMBEKE, F , (2015) LIPOGLYCOPEPTIDE ANTIBACTERIAL AGENTS IN GRAM-POSITIVE INFECTIONS: A COMPARATIVE REVIEW.DRUGS. VOL. 75. ISSUE 18. P. 2073 -2095 123 79% 2
2 SORLOZANO, A , CARRASCO, C , CABEZA, J , VILLEGAS, E , GUTIERREZ, J , (2009) ANTIMICROBIAL DEVELOPMENT IN THE ERA OF EMERGING RESISTANCE.MINI-REVIEWS IN MEDICINAL CHEMISTRY. VOL. 9. ISSUE 8. P. 938-955 101 70% 0
3 GUSKEY, MT , TSUJI, BT , (2010) A COMPARATIVE REVIEW OF THE LIPOGLYCOPEPTIDES: ORITAVANCIN, DALBAVANCIN, AND TELAVANCIN.PHARMACOTHERAPY. VOL. 30. ISSUE 1. P. 80-94 65 82% 40
4 ZHANEL, GG , CALIC, D , SCHWEIZER, F , ZELENITSKY, S , ADAM, H , LAGACE-WIENS, PRS , RUBINSTEIN, E , GIN, AS , HOBAN, DJ , KARLOWSKY, JA , (2010) NEW LIPOGLYCOPEPTIDES A COMPARATIVE REVIEW OF DALBAVANCIN, ORITAVANCIN AND TELAVANCIN.DRUGS. VOL. 70. ISSUE 7. P. 859-886 56 80% 87
5 FRAMPTON, JE , (2013) CEFTAROLINE FOSAMIL: A REVIEW OF ITS USE IN THE TREATMENT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS AND COMMUNITY-ACQUIRED PNEUMONIA.DRUGS. VOL. 73. ISSUE 10. P. 1067-1094 59 77% 25
6 KLINKER, KP , BORGERT, SJ , (2015) BEYOND VANCOMYCIN: THE TAIL OF THE LIPOGLYCOPEPTIDES.CLINICAL THERAPEUTICS. VOL. 37. ISSUE 12. P. 2619 -2636 60 76% 4
7 SCOTT, LJ , (2016) CEFTAROLINE FOSAMIL: A REVIEW IN COMPLICATED SKIN AND SOFT TISSUE INFECTIONS AND COMMUNITY-ACQUIRED PNEUMONIA.DRUGS. VOL. 76. ISSUE 17. P. 1659 -1674 55 83% 0
8 WENZLER, E , RODVOLD, KA , (2015) TELAVANCIN: THE LONG AND WINDING ROAD FROM DISCOVERY TO FOOD AND DRUG ADMINISTRATION APPROVALS AND FUTURE DIRECTIONS.CLINICAL INFECTIOUS DISEASES. VOL. 61. ISSUE . P. S38 -S47 44 85% 5
9 ROBERTS, KD , SULAIMAN, RM , RYBAK, MJ , (2015) DALBAVANCIN AND ORITAVANCIN: AN INNOVATIVE APPROACH TO THE TREATMENT OF GRAM-POSITIVE INFECTIONS.PHARMACOTHERAPY. VOL. 35. ISSUE 10. P. 935 -948 42 81% 6
10 ADAMANTIA, L , ANTONI, T , (2016) PHARMACODYNAMICS, PHARMACOKINETICS AND CLINICAL EFFICACY OF TELAVANCIN IN THE TREATMENT OF PNEUMONIA.EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. VOL. 12. ISSUE 7. P. 803 -812 43 84% 0

Classes with closest relation at Level 1


Rank Class id link
1 22341 AVIBACTAM//CEFTOLOZANE TAZOBACTAM//CEFTAZIDIME AVIBACTAM
2 2737 DAPTOMYCIN//HVISA//VANCOMYCIN
3 6235 LINEZOLID//OXAZOLIDINONE//LINEZOLID RESISTANCE
4 15552 TIGECYCLINE//GLYCYLCYCLINE//GAR 936
5 20137 ERYSIPELAS//CELLULITIS//LOWER LIMB CELLULITIS
6 7142 GLYCOPEPTIDE ANTIBIOTICS//RA VII//BALHIMYCIN
7 10027 MECA GENE//MECA//CEFOXITIN
8 158 PANTON VALENTINE LEUKOCIDIN//CA MRSA//MRSA
9 21421 STREPTOGRAMIN//QUINUPRISTIN DALFOPRISTIN//DALFOPRISTIN
10 3327 GEMIFLOXACIN//CEFDITOREN//GEMIFLOXACIN MESYLATE

Go to start page